202 related articles for article (PubMed ID: 28188377)
21. Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?
Alexandraki KI; Nikolaou A; Thomas D; Syriou V; Korkolopoulou P; Sougioultzis S; Kaltsas G
Clin Endocrinol (Oxf); 2014 May; 80(5):685-90. PubMed ID: 24118101
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of new classification of gastroenteropancreatic neuroendocrine neoplasms].
Zhu XZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):12-4. PubMed ID: 23691561
[TBL] [Abstract][Full Text] [Related]
23. [Gastric carcinoid--pathogenesis and treatment].
Bründler R; Gebbers JO; Criblez D
Schweiz Med Wochenschr; 1999 Jun; 129(25):945-50. PubMed ID: 10422189
[TBL] [Abstract][Full Text] [Related]
24. [Neuroendocrine tumors of the gastrointestinal tract].
Arnold C
Praxis (Bern 1994); 2007 Jan; 96(1-2):19-28. PubMed ID: 17256557
[TBL] [Abstract][Full Text] [Related]
25. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
[TBL] [Abstract][Full Text] [Related]
26. Morphological, molecular, and prognostic aspects of gastric endocrine tumors.
Solcia E; Rindi G; Larosa S; Capella C
Microsc Res Tech; 2000 Mar; 48(6):339-48. PubMed ID: 10738315
[TBL] [Abstract][Full Text] [Related]
27. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach.
Eissele R; Anlauf M; Schäfer MK; Eiden LE; Arnold R; Weihe E
Digestion; 1999; 60(5):428-39. PubMed ID: 10473967
[TBL] [Abstract][Full Text] [Related]
28. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
29. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.
Inzani F; Petrone G; Rindi G
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):463-470. PubMed ID: 30098710
[TBL] [Abstract][Full Text] [Related]
30. Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S; Vanoli A
J Clin Pathol; 2014 Nov; 67(11):938-48. PubMed ID: 25053544
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
33. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
34. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
Shen C; Chen H; Chen H; Yin Y; Han L; Chen J; Tang S; Yin X; Zhou Z; Zhang B; Chen Z
BMC Gastroenterol; 2016 Sep; 16(1):111. PubMed ID: 27613657
[TBL] [Abstract][Full Text] [Related]
35. Management of gastric and duodenal neuroendocrine tumors.
Sato Y; Hashimoto S; Mizuno K; Takeuchi M; Terai S
World J Gastroenterol; 2016 Aug; 22(30):6817-28. PubMed ID: 27570419
[TBL] [Abstract][Full Text] [Related]
36. Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification.
Endo S; Dousei T; Yoshikawa Y; Hatanaka N; Taniyama K; Yamauchi A; Kamiike W; Nishijima J
Int Surg; 2012; 97(4):335-9. PubMed ID: 23294075
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome.
D'Adda T; Keller G; Bordi C; Höfler H
Lab Invest; 1999 Jun; 79(6):671-7. PubMed ID: 10378509
[TBL] [Abstract][Full Text] [Related]
38. [Current WHO classification (2022) of neuroendocrine neoplasms].
Buchstab O; Knösel T
Radiologie (Heidelb); 2024 Apr; ():. PubMed ID: 38622292
[TBL] [Abstract][Full Text] [Related]
39. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
Mete O; Wenig BM
Head Neck Pathol; 2022 Mar; 16(1):123-142. PubMed ID: 35312985
[TBL] [Abstract][Full Text] [Related]
40. Carcinogenic hypergastrinemia: signet-ring cell carcinoma in a patient with multiple endocrine neoplasia type 1 with Zollinger-Ellison's syndrome.
Schott M; Sagert C; Willenberg HS; Schinner S; Ramp U; Varro A; Raffel A; Eisenberger C; Zacharowski K; Perren A; Scherbaum WA
J Clin Endocrinol Metab; 2007 Sep; 92(9):3378-82. PubMed ID: 17609302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
